Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
Tadashi MatsushitaAmy ShapiroAby AbrahamPantep AngchaisuksiriGiancarlo CastamanKatarina CepoRoseline d'OironMelissa Frei-JonesAi-Sim GohJesper HaaningSanja Hald JacobsenJohnny MahlanguMary MathiasKeiji NogamiJosephine Skovgaard RasmussenOleksandra StasyshynHuyen TranKateryna VilchevskaLaura Villarreal MartinezJerzy WindygaChur Woo YouNadezhda ZozulyaBulent ZulfikarVictor Jiménez-Yustenull nullPublished in: The New England journal of medicine (2023)
Among patients with hemophilia A or B with inhibitors, the annualized bleeding rate was lower with concizumab prophylaxis than with no prophylaxis. (Funded by Novo Nordisk; explorer7 ClinicalTrials.gov number, NCT04083781.).
Keyphrases